Form 4: C4 Therapeutics Director Donna Grogan Acquires Shares in Lieu of Cash Compensation

Director Donna Grogan acquired 1,697 shares of C4 Therapeutics common stock in lieu of cash compensation, according to a recent SEC filing.

Summary

• On April 1, 2024, Donna Grogan, a director of C4 Therapeutics, acquired 1,697 shares of common stock.
• The shares were issued as compensation for her services as a non-employee director, in lieu of cash.
• The price per share was $8.1, based on the closing market price on April 1, 2024.
• Following the transaction, Grogan directly owns 23,632 shares of C4 Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. The director taking shares instead of cash is a slightly positive signal.

Positives

• A director's decision to take shares in lieu of cash compensation can be seen as a positive sign of confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Directors often receive stock as part of their compensation packages.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a standard part of director compensation.

Key Dates